Antihypertensive effect of soybean bioactive peptides: A review

• Published in: Current opinion in pharmacology 2022-02, Vol.62, p.74-81
• Main Authors: Li, Tingna, Zhang, Xiaorui, Ren, Yuanyuan, Zeng, Yijia, Huang, Qinwan, Wang, Chao
• Format: Article
• Language: English
• Subjects: Antihypertensive Agents - pharmacology; Antihypertensive Agents - therapeutic use; Glycine max - chemistry; Glycine max - metabolism; Humans; Hypertension - drug therapy; Peptides - pharmacology; Peptides - therapeutic use; Soybean Proteins - pharmacology; Soybean Proteins - therapeutic use
• ISSN: 1471-4892; 1471-4973
• DOI: 10.1016/j.coph.2021.11.005

Hypertension is a global disease that is extremely harmful to humans. Timely lowering of blood pressure is necessary in order to avoid the occurrence of corresponding complications. This review shows that soy peptides are beneficial in resisting hypertension. One of the advantages is the abundance of raw materials for producing soybean peptides. Secondly, there are no reports of adverse reactions due to soy peptides. Moreover, they exert protective effect against hypertension-induced complications such as long-term memory impairment and kidney damage. However, there are still some obstacles associated with the development of soybean peptides. Therefore, this review is focused on statistical analysis of peptide sequences, amino acid residues, and possible targets of anti-hypertensive soybean peptides. Eventually, it proposes that application of genetic engineering technology to specifically modify the N- and C-terminal of the soybean peptides, and possible targets in identifying the likely drug targets involved in the antihypertensive effects of these peptides.